MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVH genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia

Two P-glycoprotein (P-gp) genes, MDR-1 (ABCB1) and MDR-3 (ABCB4), have been identified in humans. This study was designed to investigate whether associations exist between expression of MDR-1 and MDR-3 P-gp and other markers of poor prognosis and/or prior exposure to therapeutic agents in chronic lymphocytic leukemia (CLL). IgVH mutational status, gene usage, CD38 positivity, FISH analysis and clinical information were available on all patients. Twenty-one of 101 patients tested showed MDR-3 P-gp positivity. Associations with markers of poor prognosis or prior chemotherapy did not reach statistical significance, but MDR-3 P-gp positive patients had significantly shorter survivals than MDR-3 P-gp negative patients. MDR-1 P-gp expression (18/25) showed a strong association with unmutated IgVH genes and adverse prognosis cytogenetics (p = 0.015, p = 0.014, respectively), but was independent of prior exposure to chemotherapeutic agents. These results suggest a role for MDR-1 and MDR-3 in chemoresistant disease. This study highlights the value of determining MDR phenotype in CLL patients prior to treatment, to allow the design of novel drug regimens containing agents that reverse MDR function.

[1]  A. Nagler,et al.  In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: implications on hematological malignancies. , 2006, Leukemia research.

[2]  T. Stankovic,et al.  Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. , 2005, Blood.

[3]  I. Holland,et al.  Adventures with ABC-proteins: highly conserved ATP-dependent transporters. , 2005, Acta microbiologica et immunologica Hungarica.

[4]  R. Rosenquist,et al.  VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia , 2004, European journal of haematology.

[5]  M. Catherwood,et al.  Routine Analysis of IgVH Mutational Status in CLL Patients using BIOMED-2 Standardized Primers and Protocols , 2004, Leukemia & lymphoma.

[6]  M Hummel,et al.  Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936 , 2003, Leukemia.

[7]  U. Consoli,et al.  Multidrug resistance mechanisms in chronic lymphocytic leukaemia , 2002, British journal of haematology.

[8]  E. Moran,et al.  A new monoclonal antibody that specifically recognises the MDR‐3‐encoded gene product , 1999, International journal of cancer.

[9]  P. Borst,et al.  Hepatocyte‐specific expression of the human MDR3P‐glycoprotein gene restores the biliary phosphatidylcholine excretion absent in Mdr2 (−/−) mice , 1998, Hepatology.

[10]  E. Moran,et al.  A new mdr-1 encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded tissue without pretreatment of sections. , 1997, Journal of clinical pathology.

[11]  T. Tsuruo,et al.  Expression of the MDR1 and MDR3 gene products in acute and chronic leukemias. , 1997, Leukemia research.

[12]  Piet Borst,et al.  MDR1 P-Glycoprotein Is a Lipid Translocase of Broad Specificity, While MDR3 P-Glycoprotein Specifically Translocates Phosphatidylcholine , 1996, Cell.

[13]  A Benner,et al.  p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. , 1995, Blood.

[14]  K. Wirtz,et al.  The human MDR3 P‐glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice , 1994, FEBS letters.

[15]  A. Ho,et al.  Multidrug resistance phenotype in patients with chronic lymphocytic leukemia as detected by immunofluorescence (FACS) and northern blot analysis. , 1994, Leukemia research.

[16]  C. Huber,et al.  Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. , 1993, Journal of the National Cancer Institute.

[17]  P. Sonneveld,et al.  High expression of the mdr3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemia. , 1992, Blood.

[18]  F. Baas,et al.  Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. , 1990, Journal of the National Cancer Institute.

[19]  F. Baas,et al.  Expression of the mdr3 gene in prolymphocytic leukemia: Association with cyclosporin‐a‐induced increase in drug accumulation , 1990, International journal of cancer.

[20]  D. Housman,et al.  Isolation and expression of a complementary DNA that confers multidrug resistance , 1986, Nature.

[21]  J. Riordan,et al.  Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. , 1983, Science.

[22]  Dylan T. Jones,et al.  Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. , 2002, Haematologica.

[23]  E. Moran,et al.  Preliminary immunocytochemical studies of MDR-1 and MDR-3 Pgp expression in B-cell leukaemias. , 1999, Advances in experimental medicine and biology.

[24]  D. Rund,et al.  A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to the pathogenesis of resistant disease. , 1999, Advances in experimental medicine and biology.

[25]  T. Hogan,et al.  Multi-drug resistance in chronic lymphocytic leukemia. , 1999, Leukemia & lymphoma.

[26]  G. Mickisch.  Multidrug Resistance , 1996, Der Urologe A.

[27]  W. Walther,et al.  Point mutations in the mdr1 promoter of human osteosarcomas are associated with in vitro responsiveness to multidrug resistance relevant drugs. , 1994, European journal of cancer.

[28]  E. Newcomb,et al.  p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. , 1993, Blood.